PDGFRB overexpression	Colorectal Cancer	PDGFRB overexpression	Colorectal Cancer	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
PDGFRB overexpression	Osteosarcoma	PDGFRB overexpression	Osteosarcoma	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3
PDGFRB overexpression	Sarcoma	PDGFRB overexpression	Sarcoma	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4
PDGFRB overexpression	Thyroid Gland Papillary Carcinoma	PDGFRB overexpression	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
PDGFRB overexpression	Hepatocellular Cancer	PDGFRB overexpression	Hepatocellular Cancer	Tyrosine kinase inhibitor Sensitive: D – Preclinical Tyrosine kinase inhibitor Sensitive : D	Tyrosine kinase inhibitor Sensitive: D – Preclinical Tyrosine kinase inhibitor Sensitive : D
PDGFRB overexpression	Melanoma	PDGFRB overexpression	Melanoma	vemurafenib Resistant: D – Preclinical vemurafenib Resistant : D	vemurafenib Resistant: D – Preclinical vemurafenib Resistant : D

PDGFRB overexpression

Associations